Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A1 | P60842 | 18/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.83 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.80 |
| ▸ | RELA | Q04206 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aglafolin SCHEMBL18835920 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| Aglafolin SCHEMBL31581665 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| Aglafolin SCHEMBL20496142 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| Aglafolin SCHEMBL29369253 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| Aglafolin SCHEMBL752127 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL2629398 | 0.94 | EIF4A1 (0.88) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL23226910 | 0.93 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL19666138 | 0.93 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL18836234 | 0.93 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 | |
| SCHEMBL23463149 | 0.93 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1APAX8NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612395-B2 | Rocaglate derivatives and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| US-12403121-B2 | Anticancer rocaglamide derivatives | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250115593-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2025076059-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024016000-A2 | EIF4A INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-3998257-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2022-05-18 | — | — | EP | disclosed |
| EP-3998257-A1 | FLAVAGLINE DERIVATIVES | PIERRE FABRE MEDICAMENT (FR) | 2022-05-18 | — | — | EP | disclosed |
| US-11279708-B2 | Amidino- and amino-rocaglates as novel translation inhibitors and anticancer agents | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-03-22 | — | — | US | disclosed |
| US-10519125-B2 | Flavagline derivatives | PIERRE FABRE MEDICAMENT (FR) | 2019-12-31 | — | — | US | disclosed |
| US-8137509-B2 | Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral brønsted acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2011140334-A2 | COMPOUNDS, METHODS OF MAKING OR IDENTIFYING COMPOUNDS, AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110071124-A1 | Compounds that Inhibit Production of sAPPB and AB and Uses Thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110065786-A1 | SYNTHESIS OF ROCAGLAMIDE NATURAL PRODUCTS VIA PHOTOCHEMICAL GENERATION OF OXIDOPYRYLIUM SPECIES | TRUSTEES OF BOSTON UNIVERSITY | 2011-03-17 | — | — | US | disclosed |
| US-7816544-B2 | Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species | TRUSTEES OF BOSTON UNIVERSITY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816544-B2 | Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species | TRUSTEES OF BOSTON UNIVERSITY (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-12-03 | — | — | US | disclosed |
| US-20080177093-A1 | Synthesis of Rocaglamide Natural Products Via Photochemical Generation of Oxidopyrylium Species | TRUSTEES OF BOSTON UNIVERSITY | 2008-07-24 | — | — | US | disclosed |
| US-20080177093-A1 | Synthesis of Rocaglamide Natural Products Via Photochemical Generation of Oxidopyrylium Species | TRUSTEES OF BOSTON UNIVERSITY | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12403121-B2 | Anticancer rocaglamide derivatives | HRH3, HRH2, CYTH3 | EIF4A1 3984/4885CYP3A4 548/4885HIF1A 1200/4885 |
| US-20090299081-A1 | Asymmetric Synthesis of Rocaglamides via Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids | NFKBIA, NFKB1, NFE2L2 | EIF4A1 4735/4885CYP3A4 423/4885HIF1A 1829/4885 |
| US-11279708-B2 | Amidino- and amino-rocaglates as novel translation inhibitors and anticancer agents | EIF2B3, EIF4EBP1, G3BP1 | EIF4A1 22/4885CYP3A4 3701/4885HIF1A 3317/4885 |
| US-12612395-B2 | Rocaglate derivatives and uses thereof | GLRB, SRR, HCAR3 | EIF4A1 4223/4885CYP3A4 1122/4885HIF1A 3117/4885 |
| US-20250115593-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | ACSL3, ADSL, ACSL6 | EIF4A1 4795/4885CYP3A4 1293/4885HIF1A 4561/4885 |
| US-20110071124-A1 | Compounds that Inhibit Production of sAPPB and AB and Uses Thereof | SAP30BP, APP, BACE1 | EIF4A1 3160/4885CYP3A4 4191/4885HIF1A 3320/4885 |
| US-20110065786-A1 | SYNTHESIS OF ROCAGLAMIDE NATURAL PRODUCTS VIA PHOTOCHEMICAL GENERATION OF OXIDOPYRYLIUM SPECIES | NFKBIA, NFE2L2, NFKB1 | EIF4A1 4015/4885CYP3A4 105/4885HIF1A 1160/4885 |
| US-20080177093-A1 | Synthesis of Rocaglamide Natural Products Via Photochemical Generation of Oxidopyrylium Species | NFKBIA, NFE2L2, NFKB1 | EIF4A1 4015/4885CYP3A4 105/4885HIF1A 1160/4885 |
| US-10519125-B2 | Flavagline derivatives | GCG, GCGR, KRAS | EIF4A1 2949/4885CYP3A4 50/4885HIF1A 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.